Premium
B‐cell chronic lymphocytic leukaemia with CD8 expression: report of 10 cases and immunochemical analysis of the CD8 antigen
Author(s) -
Dao,
Susan T. Francis,
; Thomas,
Peter G. Gibson,
Cole-Sinclair,
Jason Wolf
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00928.x
Subject(s) - antigen , cd8 , biology , cytotoxic t cell , microbiology and biotechnology , immunology , cancer research , biochemistry , in vitro
We report 10 cases of B‐cell chronic lymphocytic leukaemia (B‐CLL) with expression of the T‐cell antigen CD8. The majority of patients had typical B‐cell CLL with stable and non‐progressive stage A(O) disease except for more common expression of lambda light chain and CD25. Two patients had progressive disease and required therapy, one with atypical morphological and phenotypic features. The incidence of CD8 expression was approximately 0.5% of B‐CLL patients from our institutions. Immunoprecipitation of the CD8 antigen from four of these B‐CLLs showed identity to the CD8 antigen expressed on T cells with precipitation of CD8α bands of molecular weight ~34 kD. In view of the known intracellular signalling mechanism of CD8 using the tyrosine kinase p56‐lck, we studied p56‐lck expression by Western blot and found lack of consistent expression of the CD8 surface antigen, with most lacking p56‐lck. Our report indicates that CD8 expression in B‐CLL is probably under‐recognized but is not a marker of disease progression. The CD8 on the B‐CLL surface is immunochemically identical to the antigen on T cells, but is not accompanied by its usual signalling mechanism of p56‐lck tyrosine kinase and therefore is unlikely to be a functionally active receptor.